| Today’s Big NewsMar 26, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
| By Max Bayer Moderna's next-gen COVID vaccine beat its approved counterpart in phase 3, boasting a stronger immune response. The new data is critical to Moderna's combo ambitions. |
|
|
|
By Gabrielle Masson Nanoscope Therapeutics is back with more data assessing its gene therapy that uses light-sensitive molecules to treat retinal disease. With data demonstrating vision improvement in hand, the biotech is now planning to submit the therapy for FDA approval later this year. |
By James Waldron Novo Nordisk may be racing to get an oral successor to its Wegovy weight loss sensation through clinical trials, but Viking Therapeutics is sailing up close behind. |
By Annalee Armstrong,James Waldron Investors are stocking up on Stoke Therapeutics, sending the biotech’s shares jumping over 90% in pre-market trading on the back of positive phase 1/2a data for a seizure disorder medicine. |
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now! 
|
|
By Nick Paul Taylor Praxis Precision Medicines has recorded a midphase win in epilepsy, linking the high dose of PRAX-628 to a 100% complete response rate to clear the path for a larger study in the second half of the year. |
By James Waldron With its sole remaining asset having failed to even enter the clinic, Ampio Pharmaceuticals has decided to call it a day. |
By Helen Floersh A common microbe that migrates from the mouth to the gut may be responsible for driving the progression of colorectal cancer, new findings from the Fred Hutchinson Cancer Center suggest. |
By Helen Floersh Research funded by the National Institutes of Health generated $2.46 in economic activity for every $1 of funding in 2023, a total of $92.9 billion, according to an annual report published March 25 by biomedical research advocacy organization United for Medical Research (UMR). That’s nearly $3 billion more than in 2022. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Kevin Dunleavy Maryland nonprofit Caring Cross has unveiled a partnership with the Brazilian government which is designed to provide access to advanced CAR-T and gene therapies for diseases like leukemia, lymphoma and HIV infection—and in the process provide a manufacturing model that demonstrates how to reduce the cost of these treatments in the United States and Europe. |
By Conor Hale Masimo said it will form a new company to house its home audio brands plus its high-tech Stork baby monitor system and its line of health-focused smartwatches. |
By Fraiser Kansteiner The Biden Administration and mifepristone’s manufacturer, Danco Laboratories, are getting their day in court, as they attempt to fight one of the most pivotal battles surrounding reproductive health since the Supreme Court overturned Roe v. Wade in 2022. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
|
Thursday, March 28, 2024 | 11am ET / 8am PT Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Join us to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. Register now. 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
